- Acumen Powered by Robins Kaplan LLP®
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
June 17, 2024Emily Tremblay Named IP Rising Star by Euromoney in 2024 Women in Business Law Awards
-
June 17, 2024Three Robins Kaplan Partners Named BTI Client Service All-Stars
-
June 13, 2024Brendan Johnson Named South Dakota Trial Lawyer of The Year
-
June 27, 2024Sex Abuse Litigation
-
June 10-11, 20242024 Probate and Trust Law Section Conference
-
June 11, 2024FBA 2024 Federal Practice Seminar
-
June 2024Robins Kaplan Secures Landmark $7.75 Million Verdict in Aerosol Duster Misuse Case
-
June 2024To Seize or Not to Seize: Campus Protests and Police Uses of Force
-
June 2024Communicating Your Estate Plan: A Helpful Tool, Not a Fix-All
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Pfizer Inc. v. Sandoz Inc
Post-hoc expert conclusions were not sufficient to contradict prior-art publications relating to obviousness.
July 21, 2016
![GENERICally Speaking: A Hatch Waxman Litigation Bulletin](/-/media/images/newsletters/generically-speaking-social-graphics/generically-speaking-nwsltr-badge.jpg?la=en&h=160&w=390&la=en&hash=314B8432ED62E0647D7FC4565EC18B79)
Case Name: Pfizer Inc. v. Sandoz Inc., C.A. No. 13-1110-GMS, 2016 U.S. Dist. LEXIS 52762 (D. Del. Apr. 20, 2016) (Sleet, J.)
Drug Product and Patent(s)-in-Suit: Toviaz® (fesoterodine fumarate); U.S. Patents Nos. 7,384,980 (“the ’980 patent”), 7,855,230 (“the ’230 patent”), 7,985,772 (“the ’772 patent”), 8,338,478 (“the ’478 patent”), and 6,858,650 (“the ’650 patent”)
Nature of the Case and Issue(s) Presented: Pfizer manufactures Toviaz, an extended-release tablet used to treat overactive bladder. Defendants each submitted ANDAs seeking approval to manufacture and sell generic fesoterodine. Accordingly, Plaintiffs filed suit. After the parties presented evidence relating to the issue of infringement, the court concluded that the Defendants infringed. After the validity case, the court found that Defendants did not meet their burden to clearly and convincingly establish that the patents-in-suit were obvious.
Why Pfizer Prevailed: Defendants argued that the patents-in-suit were obvious in light of the prior-art molecule tolterodine and its metabolite, 5-HMT. The court found that Defendants’ analysis was too myopic and a person of ordinary skill would not focus only on tolterodine. Instead, a number of other compounds would also be considered.
Moreover, the court was not convinced that a person of ordinary skill would modify the 5-HMT metabolite as called for in the patents-in-suit. Defendants’ expert evidence was based entirely on post-hoc conclusions, while Plaintiffs submitted prior-art publications suggesting that modifying 5-HMT would have no clinical significance. Defendants presented nothing to contradict those publications. Finally, the court found that even if a person of ordinary skill were motivated to modify 5-HMT, the skilled person would not arrive at the chemical structure of fesoterodine as disclosed in the patents-in-suit. Thus, it was not obvious to modify 5-HMT. Accordingly, the patents-in-suit were valid and infringed by Defendants.
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.